Glucagon-like peptide-1 receptor agonist dulaglutide attenuates liver injury in metabolic dysfunction-associated steatotic liver disease with diabetic mice.
Dulaglutide appears to reduce liver injury markers in a mouse model of metabolic dysfunction-associated steatotic liver disease, but further research is needed to confirm its relevance in humans.
Where it sits
this study against the rest of the dulaglutide corpusSummary and findings
Dulaglutide was evaluated for its effects on liver injury in a db/db mouse model of metabolic dysfunction-associated steatotic liver disease (MASLD). The study assessed hepatic function, histopathology, and various biomarkers after a 10-week treatment. Findings indicated alterations in liver function and markers related to oxidative stress and inflammation.
Abstract
<h4>Background</h4>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent chronic liver disease encompassing a spectrum of pathologies, including simple steatosis, steatohepatitis, fibrosis, and cirrhosis. Dulaglutide, a glucagon-like peptide-1 receptor agonist approved for diabetes treatment, has been investigated for its potential in MASLD management. This study aimed to assess the effects of dulaglutide and elucidate its potential mechanisms in a db/db mouse model of MASLD.<h4>Methods</h4>The efficacy of dulaglutide was evaluated in db/db mouse model of MASLD. After a 10-week treatment, hepatic function, histopathology, ferroptosis-related markers, inflammation, fibrosis, and dulaglutide-induced hepatic lipidomic alterations were assessed.<h4>Results</h4>Dulaglutide reduced serum ALT and AST levels and attenuated hepatic ferroptosis-related markers, as reflected by altered ACSL4 and GPX4 expression. ROS staining and Fe<sup>2+</sup> quantification demonstrated that dulaglutide mitigated elevated oxidative stress and iron accumulation in db/db mice. In parallel, dulaglutide treatment was associated with upregulation of GSH and Nrf2, as well as downregulation of MDA and 4-HNE, indicating reduced lipid peroxidation. Lipidomics analysis showed extensive remodeling of the hepatic lipid profile in db/db mice following dulaglutide treatment. In addition, dulaglutide reduced the expression of inflammatory and fibrotic markers in the db/db mouse model.<h4>Conclusion</h4>These findings indicate that dulaglutide modulates ferroptosis-related markers, inflammation, and fibrosis in MASLD mice, supporting its potential as a therapeutic option for MASLD.
Background
This study addresses the effects of dulaglutide, a glucagon-like peptide-1 receptor agonist, on metabolic dysfunction-associated steatotic liver disease (MASLD), a condition characterized by a range of liver pathologies. Previous research has indicated the potential of GLP-1 receptor agonists in managing liver conditions, but specific effects on MASLD have not been thoroughly investigated. This study is significant as it explores the mechanisms by which dulaglutide may influence liver injury in a relevant animal model.
Methods
The study utilized a db/db mouse model of MASLD to evaluate the efficacy of dulaglutide over a 10-week treatment period. Primary outcome measures included hepatic function assessed through serum ALT and AST levels, as well as histopathological evaluations. Secondary outcomes involved the assessment of ferroptosis-related markers, oxidative stress indicators, and lipidomic alterations.
Results
Dulaglutide treatment resulted in reduced serum ALT and AST levels, indicating improved hepatic function. Additionally, there were significant alterations in the expression of ferroptosis-related markers, with changes in ACSL4 and GPX4. The treatment also mitigated oxidative stress and iron accumulation, as demonstrated by ROS staining and Fe<sup>2+</sup> quantification.
Interpretation
The findings suggest that dulaglutide may have a beneficial effect on liver injury in the context of MASLD, particularly through modulation of oxidative stress and inflammatory pathways. However, while the results are statistically significant, the clinical relevance remains uncertain due to the small sample size and the use of an animal model. These confounds limit the ability to generalize the findings to human populations, and more research is needed to establish the therapeutic potential of dulaglutide in MASLD management.
Key findings
- Reduced serum ALT and AST levels after 10 weeks of dulaglutide treatment.
- Altered expression of ferroptosis-related markers ACSL4 and GPX4.
- Mitigated oxidative stress and iron accumulation as evidenced by ROS staining and Fe<sup>2+</sup> quantification.
- Upregulation of GSH and Nrf2, and downregulation of MDA and 4-HNE.
- Extensive remodeling of the hepatic lipid profile following dulaglutide treatment.
- Reduced expression of inflammatory and fibrotic markers in db/db mice.
Limitations
- Conducted in a mouse model, limiting human applicability.
- Single animal model may not capture the full spectrum of MASLD.
- No long-term follow-up data reported.
- Small sample size may affect the robustness of findings.